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ABSTRACT
Background and aims: Biomarkers of inflammation may be of clinical utility in primary sclerosing
cholangitis (PSC). We aimed to investigate the interferon gamma-related biomarkers neopterin and
kynurenine–tryptophanratio (KT-ratio) in PSC.
Methods: Circulating neopterin, tryptophan and kynurenine were measured with LC-MS/MS in mul-
tiple cross-sectional cohorts comprising in total of 524 PSC patients and 100 healthy controls from
Norway, Germany and Sweden.
Results: Neopterin and KT-ratio were significantly increased in PSC patients compared with controls in
both a discovery and a validation cohort from Norway. Furthermore, high neopterin and KT-ratio levels
were associated with a shorter transplantation-free survival in the PSC patients in the Norwegian dis-
covery cohort and the German validation cohort. However, in the validation PSC cohort from Sweden,
no relationship between neopterin and KT-ratio and liver transplantation-free survival was observed.
The correlations between neopterin and KT-ratio were moderate to strong and similar in all cohorts
(rho 0.50–0.67). Neopterin and KT-ratio also correlated with C-reactive protein (rho 0.17-0.63) and
revised Mayo risk score (rho 0.23–0.42) in all cohorts.
Conclusions: Neopterin and KT-ratio were elevated in PSC and associated with liver transplantation-
free survival in two independent PSC cohorts, highlighting a possible role of interferon gamma-driven
inflammation in the pathogenesis. However, the lack of association with survival in one of the cohorts
reduces the potential clinical value of neopterin and KT-ratioas biomarkers and highlights the need to
validate new biomarkers in PSC in multiple cohorts.
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Primary sclerosing cholangitis (PSC) is a chronic inflammatory
disease characterized by multifocal intra- and extrahepatic
bile duct strictures [1]. The nature of the disease is progres-
sive leading to liver cirrhosis and often a need for liver trans-
plantation. The disease causes are unknown, and there are
no medical interventions available to slow the disease pro-
gression [2]. Biomarkers of disease activity, severity and prog-
nosis are important tools to improve clinical practice and
facilitate development of new therapies. Circulating
biomarkers correlating with key features of the disease such
as fibrosis and inflammation may therefore be of clinical util-
ity in PSC [3,4]. The levels and predictive features of bio-
markers may also shed light on disease pathogenesis.
Multiple inflammatory pathways and immune cells are
likely involved in PSC. Macrophage activation has recently
been linked to disease severity in experimental PSC models
[5]. Circulating soluble CD14, often regarded as a macro-
phage activation marker, is increased in PSC and predict liver
transplantation-free survival. Furthermore, one of the stron-
gest genetic risk factors in PSC is a single-nucleotide
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polymorphism in the Macrophage stimulating 1 (MST1) gene
[6]. Taken together, macrophages may be relevant for dis-
ease activity and progression in PSC. Another marker of
macrophage activity is neopterin. Neopterin is produced
from guanosine triphosphate by monocytes, monocyte den-
dritic cells and macrophages after stimulation with interferon
Ç (IFNÇ), which is released from activated T-cells during the
cellular immune response [7]. Its production is increased in
many infectious, autoimmune, cardiovascular and malignant
diseases, [8,9] but data in PSC are scarce. One early study
reports higher levels of neopterin in patients with liver dis-
ease compared to healthy controls, and also in patients with
liver cirrhosis compared to non-cirrhotic patients [8].
Increased IFNÇ activity has also recently been reported in
PSC and relevant mouse models [10]. Notably, another event
occurring during IFNÇ stimulation is activation of indole-
amine 2,3-dioxygenase, which is a first-step of the kynure-
nine pathway of tryptophan catabolism. The degradation of
tryptophan to kynurenine, assessed as the kynurenine/trypto-
phan ratio (KT-ratio) is therefore another marker of IFNÇ-
related inflammatory activity which could be of relevance
in PSC.
Based on the above, the aim of this study was primarily
to analyze neopterin and KT-ratio in several cohorts of PSC
patients to investigate its possible clinical impact as bio-
marker for prognosis.
Patients and methods
Study design and patient populations
As shown in Figure 1, step I used a cross-sectional design,
comparing biomarkers in PSC patients in a Norwegian dis-
covery cohort (Norway I, n¼ 191 recruited at Oslo University
Hospital Rikshospitalet, Oslo between 2008–2015) compared
with a cohort of healthy controls recruited from the
Norwegian Bone Marrow Donor registry (Controls I, n¼ 48,
collected in Oslo between 2009–2010). For validation, a
Norwegian validation cohort (Norway II, n¼ 42 sampled at
Haukeland University Hospital, Bergen in 2017–2018) was
compared with a second cohort of healthy controls (Controls
II, n¼ 52, collected in Oslo between 2009 and 2010). In step
II, the aim was to investigate the association of biomarkers
with liver transplantation-free survival and other clinical char-
acteristics (Figure 1). The Norway I patients were used as dis-
covery cohort and validation was attempted in a German
cohort (Germany, n¼ 150 recruited at the University Hospital
in Heidelberg, Heidelberg between 2008 and 2017) and a
Swedish cohort (Sweden, n¼ 141 recruited at Karolinska
University Hospital, Stockholm between 2008 and 2012). The
population characteristics are shown in Table 1. The cohort
sizes were determined by sample availability.
Diagnosis of PSC was based on typical findings on mag-
netic resonance cholangiography or endoscopic retrograde
cholangiography according to established criteria [11]. The
first pathological radiologic finding defined the time of PSC
diagnosis. Clinical and demographic information including
laboratory data were acquired from patient records and
research databases. Inflammatory bowel disease was diag-
nosed based on endoscopy and histological findings, accord-
ing to accepted criteria [12]. Revised Mayo risk score was
calculated according to the established algorithm [13]. Liver
stiffness was measured at the time of blood sampling in the
Norway II cohort as well as in a subset of the Swedish
patients, using transient elastography (Fibroscan, Echosens,
Paris, France) in both cohorts.
Plasma was collected from the Norwegian patient and
control cohorts (no previous freeze-thaw cycles) and serum
from the German and Swedish patient cohorts (at least one
previous freeze-thaw cycle per sample), according to a stand-
ard protocol in each country.
Biochemical analyses
Plasma and serum concentrations of neopterin, kynurenine
and tryptophan were analyzed in the same assay using liquid
chromatography-tandem mass spectrometry (LC-MS/MS) as
previously described [14]. The inter-assay variation
Figure 1. Overall study design. The figure shows the study design and the use of the four included PSC cohorts and two cohorts of healthy controls. In step I, asso-
ciations with PSC are analyzed by comparing PSC patients with healthy controls in two independent cohorts. In step II, the association between liver transplant-
ation-free survival and the biomarkers are investigated in three independent cohorts.
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coefficients of the assays are for tryptophan 6%, kynurenine
6–9% and neopterin 6–10%, while the intra-assay variation
coefficients are 3–4% for tryptophan and 3–5% for kynure-
nine and neopterin. Samples were analyzed 82 samples in
each batch, with eight additional calibrators/quality control
samples in each batch. Standard biochemical analyses were
performed as part of clinical routine, including liver function
tests, CRP and international normalized ratio (INR).
Statistical analyses
Unless stated otherwise, data are presented as median
(range), except survival (in years) which is presented as mean
(95% CI).The Mann–Whitney U-test was applied for continuous
variables. Bivariate correlations were assessed by the
Spearman’s rank correlation test (rho). Primary endpoints were
liver transplantation or death. Liver transplantation-free sur-
vival was analyzed using Kaplan-Meier plots and log-rank
tests, and univariate and multivariate Cox regression. In multi-
variable regression, patients lacking Mayo risk score data
were excluded. The KT-ratio was calculated as
100kynurenine:tryptophan (mmol:mmol). Cut-offs for high ver-
sus low levels of neopterin and KT-ratio were defined by
Youden’s index when performing analysis of receiver operat-
ing characteristics/area under the curve. Statistical analyses
were performed using SPSS (version 25; SPSS, Inc., Chicago,
IL), GraphpadPrism (version 8, GraphPad Software, San Diego,
CA) and MedCalc (MedCalc Software bvba, Ostend, Belgium).
P-values <.05 were considered statistically significant.
Ethics
Written informed consent was obtained from each study par-
ticipant. The study was carried out in accordance with the
Declaration of Helsinki. The Regional Committee for Medical
and Health Research Ethics of South-Eastern Norway
approved the study (reference 2015/2140).
Results
Step I discovery and validation. Increased neopterin
and KT-ratio in Norwegian PSC patients
Neopterin levels were higher in the plasma of PSC patients
in Norway I, median (range) 11.9 (5.8–74.4), than in Controls
I, 10.2 (4.7–42.0), p¼ .003 (Figure 2(A)). This finding was vali-
dated when comparing Norway II PSC patients with Controls
II, 11.9 (5.7–27.9), vs. 11.4 (4.9–20.2), p¼ .05 (Figure 2(B)).
Likewise, KT-ratio was increased in PSC in both Norway I and
Norway II compared with controls (Figure 2(C–D)). Neopterin
and KT-ratio correlated strongly in both the Norway I and
Norway II cohorts, rho: 0.61, p< .001 and rho: 0.50, p¼ .001,
respectively (Figure 2(E–F)).
Step II discovery. Neopterin and KT-ratio associated
with survival in Norwegian PSC patients
Next, the associations between neopterin and KT-ratio and
liver transplantation-free survival were investigated in the
discovery PSC cohort Norway I. PSC patients who died or
were liver-transplanted (reached an endpoint) during follow-
up (n¼ 87, 45%) had higher neopterin levels than those who
did not, 13.6 (6.6–74.4) compared with 11.2 (5.8–43.3) nmol/
L, respectively (p< .001, Figure 3(A)). When stratifying neo-
pterin into quartiles, a Kaplan–Meier survival analysis showed
an inverse association between higher levels of neopterin
and liver transplantation-free survival, log rank p< .001
(Figure 3(B)).
Similar results were observed in Norway I for KT-ratio,
which was higher in PSC patients who reached an endpoint
during follow-up compared with those who did not (Figure
3(C)). Accordingly, KT-ratio stratified into quartiles showed an
inverse association with liver transplantation-free survival in
the Norway I cohort (p< .001, Figure 3(D)).
Both neopterin and KT-ratio were able to differentiate PSC
patients who reached an endpoint during follow-up from
those who did not, with AUCs of 0.68 (95% CI 0.61–0.75) and













Males, n (%) 151 (79) 33 (79) 94 (63) 95 (67) 28 (58) 31 (60)
Age at sampling, years,
median (range)
41 (16–72) 50 (19–84) 43 (18–74) 42 (21–77) 40 (29–55) 40 (28–56)
Age at PSC diagnosis, years,
median (range)
35 (13–72) 38 (12–73) – 34 (8–72) – –
IBD, n (%) 139 (74) 35 (83) 96 (64) 105 (74) – –
Cholangiocarcinoma, n (%) 24 (13) 2 (2) 10 (7) 5 (4) – –
Follow-up, years, median (range) 4 (0–8) NA 4 (0–10) 8 (0–11) – –
Liver transplantation, n (%) 67 (35) NA 9 (6) 37 (26) – –
Deaths, n (%) 20 (10) NA 7 (5) 10 (7) – –
Mayo risk score, median (range) 0.27 (-2.37–4.13) 0.45 (-1.88–2.95) 0.10 (-2.2–5.1) 0.04 (-1.8–3.3) – –
ALP, U/L, median (range) 237 (51–1459) 168 (59–863) 182 (47–1622) 126 (30 1350) – –
ALT, U/L, median (range) 97 (14–1008) 58 (11–657) 50 (6–489) 49 (9–436) – –
AST, U/L, median (range) 77 (16–1683) 50 (18–299) 46 (5–1178) 40 (14–311) – –
Albumin g/L, median (range) 40 (23–51) 45 (31–51) 43 (20–49) 38 (22–48) – –
Total bilirubin, mmol/L,
median (range)
24 (3–591) 11.50 (5–99) 15 (3–460) 12 (3–160) – –
Creatinine, mmol/L, median (range) 65 (5–137) 74 (54–98) 68 (33–187) 70 (38–105) – –
Platelets x109, median (range) 276 (22–903) 236 (80–430) 250 (47–1127) 235 (36–555) – –
ALP: alkaline phosphatase; ALT: alanine aminotransferase; AST: aspartate aminotransferase; IBD: inflammatory bowel disease; NA: not applicable.
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0.69 (95% CI 0.62–0.76), respectively. The optimal cut-offs
were 11.8 nmol/L for neopterin (Figure 3(E)) and 2.89 for KT-
ratio (Figure 3(F)).
Step II validation. Neopterin and KT-ratio associated
with survival in German PSC patients
In line with the findings in Norway I, patients reaching an
endpoint in the German PSC cohort (n¼ 16, 11%) had higher
neopterin concentration than patients not reaching an end-
point, 18.3 (7.0–105.0) compared with 10.0 (3.0–145.0) nmol/
L, p¼ .006 (Figure 4(A)). When stratifying neopterin into
quartiles, a Kaplan–Meier survival analysis validated the
inverse relationship between higher levels of neopterin and
liver transplantation-free survival (p¼ .012, Figure 4(B)). High
neopterin as defined by the 11.8 nmol/L cut-off was strongly
associated with reduced liver transplantation-free survival
also in the German cohort (Figure 4(C)).
In line with the results for neopterin, KT-ratio was also
higher in the German patients reaching an endpoint than in
those without endpoint (Figure 5(A)). Accordingly, KT-ratio
stratified into quartiles associated with liver transplantation-



































































































































Figure 2. Neopterin and KT-ratio in PSC patients compared with healthy controls. (A-B) Increased neopterin concentration in two cohorts of Norwegian PSC
patients compared with controls. (D-E) Increased kynurenine–tryptophan-ratio (KT-ratio) in two cohorts of Norwegian PSC patients compared with controls. (C and
F) Moderate-to-strong correlation between neopterin and KT-ratio in both the Norway I (n¼ 191) and Norway II (n¼ 42) cohorts of PSC patients. p.05, p<.01,p< 0.001. Results in (A), (B), (D), (E) are shown as median, interquartile range on a logarithmic scale.
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High KT-ratio (>2.89) was strongly associated with reduced
liver-transplantation-free survival (Figure 5(C)).
Step II validation. Neopterin and KT-rationot associated
with survival in Swedish PSC patients
In the Swedish validation cohort, neopterin was distinctly higher
than seen in the three other PSC cohorts (Figure 4(D)). N¼ 134
(96%) of the Swedish patients had neopterin >11.8nmol/L com-
pared with 98 (51%) of the PSC patients in Norway I, 21 (50%)
in Norway II and 63 (42%) in the German cohort. In the Swedish
cohort, patients who reached an endpoint during follow-up had
neopterin levels similar to the patients without an endpoint
(Figure 4(E)). Correspondingly, a Kaplan-Meier analysis after strati-
fying neopterin into quartiles showed no association between
neopterin levels and liver transplantation-free survival (Figure
4(F)). The predictive effect of high neopterin (>11.8nmol/L) was
not analyzed since only 6 (4%) were defined as low.
KT-ratio was lower in the Swedish PSC patients than in the
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High KT-ratio Norway I
KT-ratio <2.89
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Figure 3. Neopterin, KT-ratio and liver transplantation-free survival in the Norwegian discovery cohort. (A) Increased neopterin concentration in PSC patients in the
Norway I cohort, who were liver transplanted or died during follow-up. (B) Liver transplantion-free survival in the PSC patients in the Norway Icohort according to
quartiles of neopterin, showing shorter liver transplant-free survival with higher values of neopterin (p< 0.001). (C) Higher KT-ratio level in PSC patients from the
Norway I cohort, who were liver transplanted or died during follow-up. (D) Liver transplantation-free survival in the PSC patients in the Norway I cohort according
to quartiles of KT-ratio, showing shorter liver transplant-free survival with higher values of KT-ratio (P< 0.001). (E) PSC patients in the Norway I cohort with neo-
pterin > 11.8 nmol/L had significantly shorter liver transplant-free survival (log rank p< 0.001). (F) PSC patients in the Norway I cohort with KT-ratio > 2.89 had
significantly shorter liver transplantation-free survival (log rank p< 0.001). : p< 0.001; KT-ratio: Kynurenine–tryptophan-ratio. Results in (A), (C) are shown as
median, interquartile range on a logarithmic scale.
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differences between Sweden and Germany or Norway II (Figure
5(D)). KT-ratio was similar in Swedish PSC patients with and
without endpoint (Figure 5(E)), and accordingly, KT-ratio strati-
fied into quartiles (Figure 5(F)) or above the cut-off of 2.89
(Supplementary Figure 1) was not associated liver transplant-
ation-free in the cohort of Swedish patients.
The correlations between KT-ratio and neopterin were
similar in the German and Swedish cohorts (rho: 0.67,
p< .001 and rho: 0.62, p< .001, respectively, Supplementary
Figure 2A-B), which was within the range of the observations
in the two Norwegian cohorts (Figure 2(C–D)).
Correlations between neopterin and KT-ratio and
disease severity
Neopterin and Mayo risk score showed a positive correlation
in all PSC cohorts (Figure 6), with Spearman’s rho ranging
from 0.23 in the German cohort to 0.42 in the Norway II
cohort (Supplementary Figure 3). Similar correlations were
observed between KT-ratio and Mayo risk score, ranging from
0.26 in the German cohort to 0.40 in the Norway I cohort
(Supplementary Figure 4). In a Cox regression model including
neopterin and Mayo risk score, high neopterin (>11.8nmol/L)
predicted survival independent of Mayo risk score in the
Norway I cohort, HRhigh neopterin of 1.62 (95% CI 1.0–2.6),
p¼ .044, but not significantly in the German cohort, HRhigh
neopterin 2.8 (95% CI 0.8–9.0), p¼ .093. In a similar analysis in
the Swedish cohort, high neopterin (as defined by above
median, 21.1nmol/L, because of higher values) did not, HR 0.7
(95% CI 0.4–1.3). The results were similar for high KT-ratio
(>2.89) corrected for Mayo risk score (data not shown).
Liver stiffness as measured by transient elastography
correlated with neopterin and KT-ratio in the Norway II
cohort, rho 0.31, p¼ .045 and rho 0.34, p¼ .027, respect-
ively. In the Swedish patients, neither neopterin nor KT-
ratio correlated with transient elastography (rho 0.03 for
both). Median transient elastography was 7.9 (range 4–61)
kPa in the Norway II cohort and 7.1 (3–26) in the subset
of the Swedish patients, with 6/42 and 5/57, respectively,
above the established cut-off of 14.4 kPa for cirrhosis [15].
There was a significant correlation between transient elas-
tography and Mayo risk score in both the Norway II and




























































































































































































































Figure 4. Neopterin in German and Swedish PSC patients. (A) Increased neopterin concentration in PSC patients from Germany, who were liver transplanted or
died during follow-up. (B) Liver transplantation-free survival in the German PSC according to quartiles of neopterin, showing shorter liver transplant-free survival
with higher values of neopterin (log rank p¼ 0.012). (C) German PSC patients with neopterin > 11.8 nmol/L had significantly shorter liver transplant-free survival
(log rank p¼.003). (D) Neopterin concentrations in all investigated cohorts, showing higher levels in Swedish PSC compared with Norway I (p<.001), Norway II
(p<.001) and Germany (p<.001). E. No difference in neopterin concentration in PSC patients from Sweden who reached an endpoint (liver transplantation or death)
or not during follow-up. F. Liver transplantation-free survival in the PSC patients from Sweden according to quartiles of KT-ratio, showing no significant association
(log rank p¼.07). p<.01. Results in (A), (D), (E) are shown as median, interquartile range on a logarithmic scale.
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Correlations with clinical and biochemical
characteristics in all cohorts
Given the deviating results in the Swedish validation cohort,
we explored the cohort characteristics to identify possible
clinical differences between the patients which could explain
the observations. The Swedish PSC cohort was demographic-
ally relatively similar to the Norway I cohort (Table 1).

















































































































































































































Figure 5. KT-ratio in German and Swedish PSC patients. (A) Increased KT-ratio in PSC patients from Germany, who were liver transplanted or died during follow-
up. (B) Liver transplantation-free survival in the German PSC according to quartiles of KT-ratio, showing shorter liver transplant-free survival with higher values of
KT-ratio (log rank p¼.002). (C) German PSC patients with KT-ratio > 2.89 had significantly shorter liver transplant-free survival (log rank p¼.001). (D) KT-ratio com-
pared between all investigated cohorts, showing higher levels in the Norway I PSC patients compared with patients from Sweden (p¼.018), otherwise no differen-
ces between the patient cohorts. (E) No difference in KT-ratio in PSC patients from Sweden who reached an endpoint (liver transplantation or death) or not during
follow-up. (F) Liver transplantation-free survival in the PSC patients from Sweden according to quartiles of KT-ratio, showing no significant association (log rank
p¼.28) p<.001. KT-ratio: Kynurenine–tryptophan-ratio. Results in (A), (D), (E) are shown as median, interquartile range on a logarithmic scale.
Figure 6. Neopterin and KT-ratio correlations with biochemistry and clinical characteristics. Heat map showing the correlation (Spearman rank) of clinical and bio-
chemical characteristics of the PSC patient cohorts and neopterin and kynurenine-tryptophan ratio, respectively.The exact rho values are shown in Supplementary
Figure 5. : p.05, : p<.01, : p<.001. MRS: Revised Mayo risk score; CRP: C reactive protein; ALP: alkaline phosphatase; ALT: alanine aminotransferase; AST:
aspartate aminotransferase.
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and neopterin and KT-ratio are shown in Figure 6 and
Supplementary Figure 5. Notably, neopterin and KT-ratio cor-
related with CRP in all investigated cohorts (rho 0.17–0.63).
Considering the Swedish cohort specifically, the perhaps
most noteworthy difference was a lack of association of neo-
pterin and KT-ratio with bilirubin, which was present in the
other cohorts. Data on medication was available from the
German cohort, where all patients were on ursodeoxycholic
acid, 35 (23%) on immunosuppression 44 (29%) on 5-ASA
therapy. Neopterin and KT-ratio were not different between
patients with and without immunosuppression or 5-ASA
(data not shown). In the German cohort, patients with con-
comitant IBD had higher neopterin and KT-ratiothan patients
without IBD (p< .05), while neopterin or KT-ratio did not
vary with IBD status in the three other cohorts
(Supplementary Figures 6–7).
Discussion
In this study of in total 524 PSC patients from three coun-
tries, circulating neopterin and KT-ratio were higher in PSC
patients compared with healthy controls in two independent
Norwegian cohorts. In addition, increasing levels of neopterin
and KT-ratio associated with reduced liver transplantation-
free survival in independent cohorts from Norway and
Germany, while in a PSC cohort from Sweden, neither neo-
pterin nor KT-ratio predicted endpoints, despite similar
patient demographics and correlations with biochemistry
and Mayo risk score. Overall, the results suggest that IFNÇ-
driven inflammation occurs in PSC patients, but the non-con-
sistent association with survival suggests either that
neopterin or tryptophan degradation to kynurenine at a
given time point do not determine survival per se, or that
circulating levels of neopterin or kynurenine do not always
accurately reflect the process in the liver. It also highlights
the need for validating biomarkers in multiple PSC cohorts
before implementation in clinical practice.
Neopterin and KT-ratio were elevated in PSC compared
with healthy controls. In the published literature, one small
study has shown increased kynurenine and unchanged tryp-
tophan in PSC, which would lead to increased KT-ratio [16].
Also, neopterin has been observed to be increased in mul-
tiple chronic liver diseases, including autoimmune etiologies,
but no PSC patients were investigated [8,17]. Both neopterin
and KT-ratio increase with IFNc signaling, and the data are
therefore supported by the observations of increased
IFNcand the IFNc-driven chemokines CXCL10 and CXCL11
found in serum in small cohorts of PSC patients [10,18]. IFNc
concentration was also increased in PSC bile, [19] increased
IFNc mRNA expression has been found in PSC explants, [20]
and more IFNc-producing T cells were found in colons of
ulcerative colitis patients with concomitant PSC compared
with ulcerative colitis patients without PSC [21]. Furthermore,
the main source of neopterin is macrophages, and the results
would fit with the observation of increased numbers of mac-
rophages in PSC livers and accumulation of macrophages in
the peribiliary areas of the liver [5,22–24]. Overall, there is
therefore strong reason to believe that IFNc-driven
inflammation with subsequent increased neopterin and KT-
ratio occurs in PSC.
Since biomarkers of inflammation in PSC could reflect dis-
ease activity in the biliary tree and subsequently progression
of disease, we investigated the relationship with liver trans-
plantation-free survival. There was a strong association
between high neopterin and KT-ratio and reduced survival in
both the Norwegian discovery cohort and the German
cohort. Previous studies have shown a predictive value in
PSC of biomarkers of inflammation like soluble CD14 and
interleukin-8 [25,26]. Furthermore, IFNÇ signaling has been
shown to be an important mediator in the progression of
the PSC-relevant mouse Mdr2 knockout model, [10] and
inhibition of macrophage recruitment in an acute model of
sclerosing cholangitis attenuated liver injury, [5] both sup-
porting the potential relevance of neopterin and KT-ratio as
biomarkers of disease severity in PSC. An important question
is whether increased neopterin and KT-ratio reflect increased
disease activity or later disease stage. There were only mod-
erate correlations between neopterin and Mayo risk score in
the included cohorts, and only a moderate correlation
between neopterin and KT-ratio and liver stiffness in the
Norway II cohort. Furthermore, both predicted liver trans-
plantation-free survival independent from Mayo risk score in
the Norway I cohort, while in the German cohort neopterin
and KT-ratio were no longer significantly associated with sur-
vival after correction for Mayo risk score, although the risk
estimates were higher in the German than the Norway I
cohort. Overall, these observations may suggest the predict-
ive values of neopterin and KT-ratio reflect disease activity in
PSC and not only disease stage, but it cannot be concluded
with certainty.
In contrast to the findings in the Norwegian and German
PSC patients, there were no signs of association of neopterin
or KT-ratio with survival in the Swedish cohort. Notably, the
neopterin concentrationswere much higher in the Swedish
patient serum than in the German serum or Norwegian
plasma, potentially reflecting differences in critical preanalyti-
cal factors. Speaking against that being the case, KT-ratio
were similar in the cohorts and the well-known strong correl-
ation between KT-ratio and neopterin, [27] was observed in
all cohorts, despite neopterin, kynurenine and tryptophan
having different biochemical characteristics including more
stable concentrations during storage for kynurenine and
tryptophan than neopterin [28]. Taken together, this sug-
gests that the pre-analytical factors do not explain the het-
erogeneity observed.
The deviating results in the Swedish cohorts could reflect
true biological and clinical differences in the Swedish
patients. Notably, there was no correlation of liver stiffness
with neopterin or KT-ratio in the subset investigated in the
Swedish cohort, in contrast to the observations in the
Norway II cohort. However, the overall patient characteristics
and biochemistry were not conspicuously different. Also,
Mayo risk score predicted liver transplantation-free survival
in all three cohorts and both neopterin and KT-ratio corre-
lated with Mayo risk score in all three cohorts, although the
correlation with CRP was weaker and with bilirubin absent in
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the Swedish patients. Importantly, while the proportion of
patients with IBD was comparable in the patient cohorts, it
cannot be excluded that IBD activity may differ. Intestinal
indoleamine 2,3-dioxygenase activity may influence plasma
KT-ratio, [29] and it has previously been shown that KT-ratio
may be elevated in patients with IBD, particularly pro-
nounced in those with severe disease activity [30]. However,
the differences in neopterin and KT-ratio between PSC
patients with and without IBD were minor and only statistic-
ally significant in the German cohort, speaking against a
major effect of IBD in this study.
The strengths of the present study are in particular the
large number of patients from multiple cohorts from three
countries, long follow-up of the patients, in addition to the
use of well-validated and precise LC-MS/MS-based analysis
methodology. Regarding limitations, the use of plasma in the
Norwegian samples and serum in the German and Swedish
samples as well as differences in storage time may add some
heterogeneity, although only similar samples were compared.
Furthermore, all serum samples were thawed and frozen at
least once, with could add some additional variation to the
subsequent biochemical analyses. The large number of sam-
ples and hence multiple batches analyzed and the inter- and
intra-assay variation of the analyses could also influence the
results, although this was minimized by the use of internal
standards and controls. Regarding clinical data, there is a
lack of detailed information for many of the patients on dis-
ease stage besides core biochemistry and complications of
cirrhosis, and there is a lack of details on the distribution
and activity of the concomitant IBD. The heterogeneity of
the results makes a clear interpretation difficult and reduces
the possible clinical value of neopterin or KT-ratio as candid
biomarkers in PSC. Notably, among other investigated bio-
markers in PSC, fibrosis markers like enhanced liver fibrosis
test and pro-C3 appear to be perhaps stronger than inflam-
mation markers, as exemplified by interleukin-8, which was
no longer and independent predictor of survival after correc-
tion for enhanced liver fibrosis test [4,26,31,32]. Still, neo-
pterin and KT-ratio are clearly elevated in PSC compared
with controls, and the survival effects observed in two of the
cohorts were strong. It is therefore still possible that thera-
pies targeting inflammatory pathways are of relevance in
PSC. However, the study highlights the general need for vali-
dating biomarkers in multiple PSC cohorts before clinical
implementation.
Conclusions
Overall, neopterin and KT-ratio were elevated in PSC and
associated with liver transplantation-free survival in two inde-
pendent PSC cohorts, highlighting a possible role of IFNc-
driven inflammation in the pathogenesis and these markers
as measures of prognosis and disease activity in PSC.
However, the lack of association with survival in one of the
investigated cohorts questionsthe potential clinical value of
neopterin and KT-ratio and highlights the need to validate
new biomarkers in PSC in multiple cohorts, preferably with
detailed characterization of stage and IBD activity taken
into account.
Acknowledgements
Liv Wenche Thorbjørnsen at the Norwegian PSC Research Center is
acknowledged for help with biobank material. The Norwegian Bone
Marrow Donor Registry is acknowledged for providing healthy controls.
Ethics approval
The study was carried out in accordance with the Declaration of
Helsinki. The Regional Committee for Medical and Health Research
Ethics of South-Eastern Norway approved the study (reference 2015/
2140). Written informed consent was obtained from allstudy participants.
Author contributions
(i) Guarantor of the article: Johannes R. Hov is acting as the sub-
mission’s guarantor.
(ii) Specific author contributions: AKD, MT and JRH conceived and
planned the study. AKD, CR, AB, RV, TF, THK, MV, MK, JRH collected sam-
ples and clinical data. ØM and PMU performed biochemical analyses.
AKD, MK and JRH performed statistical analyses. AKD, CR, AB, MT, ØM,
PMU, MV, MK and JRH contributed to the interpretation of the results.
AKD and JRH wrote the first draft.
(iii) All authors critically reviewed and revised the manuscript and
approved the final version.
Disclosure statement
There was no conflict of interest.
Funding
AKD and JRH were funded by the Research Council of Norway (no.
240787/F20). MK was funded by the Regional Health Authority of South-
Eastern Norway (no. 2016067).
ORCID
Johannes R. Hov http://orcid.org/0000-0002-5900-8096
References
[1] Cullen S, Chapman R. Primary sclerosing cholangitis. Autoimmun
Rev. 2003;2(6):305–312.
[2] Karlsen TH, Folseraas T, Thorburn D, et al. Primary sclerosing
cholangitis - a comprehensive review. J Hepatol. 2017;67(6):
1298–1323.
[3] Dhillon AK, Kremer AE, Kummen M, et al. Autotaxin activity pre-
dicts transplant-free survival in primary sclerosing cholangitis. Sci
Rep. 2019;9(1):8450.
[4] de Vries EMG, Farkkila M, Milkiewicz P, et al. Enhanced liver fibro-
sis test predicts transplant-free survival in primary sclerosing
cholangitis, a multi-centre study. Liver Int. 2017;37(10):1554–1561.
[5] Guicciardi ME, Trussoni CE, Krishnan A, et al. Macrophages con-
tribute to the pathogenesis of sclerosing cholangitis in mice. J
Hepatol. 2018;69(3):676–686.
[6] Melum E, Franke A, Schramm C, et al. Genome-wide association
analysis in primary sclerosing cholangitis identifies two non-HLA
susceptibility loci. Nat Genet. 2011;43(1):17–19.
[7] Hamerlinck FF. Neopterin: a review. Exp Dermatol. 1999;8(3):
167–176.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY 451
[8] Wilmer A, Nolchen B, Tilg H, et al. Serum neopterin concentra-
tions in chronic liver disease. Gut. 1995;37(1):108–112.
[9] Pihlstrom H, Mjoen G, Marz W, et al. Neopterin is associated with
cardiovascular events and all-cause mortality in renal transplant
patients. Clin Transplant. 2014;28:111–119.
[10] Ravichandran G, Neumann K, Berkhout LK, et al. Interferon-
c-dependent immune responses contribute to the pathogenesis
of sclerosing cholangitis in mice. J Hepatol. 2019;71(4):773–782.
[11] Chapman R, Fevery J, Kalloo A, American Association for the
Study of Liver Diseases, et al. Diagnosis and management of pri-
mary sclerosing cholangitis. Hepatology. 2010;51(2):660–678.
[12] Lennard-Jones JE. Classification of inflammatory bowel disease.
Scand J Gastroenterol Suppl. 1989;170:2–6.
[13] Kim WR, Therneau TM, Wiesner RH, et al. A revised natural history
model for primary sclerosing cholangitis. Mayo Clin Proc. 2000;
75(7):688–694.
[14] Midttun O, Hustad S, Ueland PM. Quantitative profiling of bio-
markers related to B-vitamin status, tryptophan metabolism and
inflammation in human plasma by liquid chromatography/tan-
dem mass spectrometry. Rapid Commun Mass Spectrom. 2009;
23(9):1371–1379.
[15] Corpechot C, Gaouar F, El Naggar A, et al. Baseline values and
changes in liver stiffness measured by transient elastography are
associated with severity of fibrosis and outcomes of patients with
primary sclerosing cholangitis. Gastroenterology. 2014;146(4):
970–979. quiz e915–976.
[16] Bell LN, Wulff J, Comerford M, et al. Serum metabolic signatures
of primary biliary cirrhosis and primary sclerosing cholangitis.
Liver Int. 2015;35(1):263–274.
[17] Gulcan EM, Tirit I, Anil A, et al. Serum neopterin levels in children
with hepatitis-B-related chronic liver disease and its relationship
to disease severity. World J Gastroenterol. 2008;14(44):6840–6843.
[18] Langeneckert AE, Lunemann S, Martrus G, et al. CCL21-expression
and accumulation of CCR7þ NK cells in livers of patients with pri-
mary sclerosing cholangitis. Eur J Immunol. 2019;49(5):758–769.
[19] Zhou T, Bartelheimer K, Ruping F, et al. Intrahepatic biliary stric-
tures after liver transplantation are morphologically similar to pri-
mary sclerosing cholangitis but immunologically distinct. Eur J
Gastroenterol Hepatol. 2020;32(2):276–284.
[20] Mueller T, Beutler C, Pico AH, et al. Enhanced innate immune
responsiveness and intolerance to intestinal endotoxins in human
biliary epithelial cells contributes to chronic cholangitis. Liver Int.
2011;31(10):1574–1588.
[21] Gwela A, Siddhanathi P, Chapman RW, et al. Th1 and innate
lymphoid cells accumulate in primary sclerosing cholangitis-asso-
ciated inflammatory bowel disease. J Crohns Colitis. 2017;11(9):
1124–1134.
[22] Chen YY, Arndtz K, Webb G, et al. Intrahepatic macrophage pop-
ulations in the pathophysiology of primary sclerosing cholangitis.
JHEP Rep. 2019;1(5):369–376.
[23] Govaere O, Cockell S, Van Haele M, et al. High-throughput
sequencing identifies aetiology-dependent differences in ductular
reaction in human chronic liver disease. J Pathol. 2019;248(1):
66–76.
[24] Kunzmann LK, Schoknecht T, Poch T, et al. Monocytes as poten-
tial mediators of pathogen-induced Th17 differentiation in
patients with primary sclerosing cholangitis (PSC). Hepatology.
2020;72(4):1310–1326.
[25] Dhillon AK, Kummen M, Troseid M, et al. Circulating markers of
gut barrier function associated with disease severity in primary
sclerosing cholangitis. Liver Int. 2019;39(2):371–381.
[26] Vesterhus M, Holm A, Hov JR, et al. Novel serum and bile protein
markers predict primary sclerosing cholangitis disease severity
and prognosis. J Hepatol. 2017;66(6):1214–1222.
[27] Fuchs D, Moller AA, Reibnegger G, et al. Increased endogenous
interferon-gamma and neopterin correlate with increased degrad-
ation of tryptophan in human immunodeficiency virus type 1
infection. Immunol Lett. 1991;28(3):207–211.
[28] Schrocksnadel K, Wirleitner B, Winkler C, et al. Monitoring trypto-
phan metabolism in chronic immune activation. Clin Chim Acta.
2006;364(1–2):82–90.
[29] Laurans L, Venteclef N, Haddad Y, et al. Genetic deficiency of
indoleamine 2,3-dioxygenase promotes gut microbiota-mediated
metabolic health. Nat Med. 2018;24(8):1113–1120.
[30] Gupta NK, Thaker AI, Kanuri N, et al. Serum analysis of trypto-
phan catabolism pathway: correlation with Crohn’s disease activ-
ity. Inflamm Bowel Dis. 2012;18(7):1214–1220.
[31] Vesterhus M, Hov JR, Holm A, et al. Enhanced liver fibrosis score
predicts transplant-free survival in primary sclerosing cholangitis.
Hepatology. 2015;62(1):188–197.
[32] Nielsen MJ, Thorburn D, Leeming DJ, et al. Serological markers of
extracellular matrix remodeling predict transplant-free survival in
primary sclerosing cholangitis. Aliment Pharmacol Ther. 2018;
48(2):179–189.
452 A. K. DHILLON ET AL.
